Last reviewed 2026-04-19 · How we verify

ETIROXATE

Phase 2 active Small molecule

ETIROXATE is a etiroxate drug. It is currently in Phase 2 development.

Etiroxate works by inhibiting platelet aggregation, but the exact molecular details are unclear.

Etiroxate is a small molecule drug in the etiroxate class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. Etiroxate's indications, half-life, bioavailability, and generic manufacturers are also unknown. As a result, there is limited information available on its commercial status, safety considerations, or off-patent status. Further research is needed to understand this drug's properties and potential uses.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETIROXATE
Drug class	etiroxate
Modality	Small molecule
Therapeutic area	Hematology
Phase	Phase 2

Mechanism of action

Imagine your blood as a liquid with tiny particles called platelets that help it clot when you're injured. Etiroxate is thought to slow down the movement of these platelets, making it harder for them to clump together and form clots. This can help prevent blood clots from forming in the first place.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ETIROXATE CI brief — competitive landscape report
ETIROXATE updates RSS · CI watch RSS

Frequently asked questions about ETIROXATE

What is ETIROXATE?

ETIROXATE is a etiroxate drug.

How does ETIROXATE work?

Etiroxate works by inhibiting platelet aggregation, but the exact molecular details are unclear.

What drug class is ETIROXATE in?

ETIROXATE belongs to the etiroxate class. See all etiroxate drugs at /class/etiroxate.

What development phase is ETIROXATE in?

ETIROXATE is in Phase 2.

Drug class: All etiroxate drugs
Therapeutic area: All drugs in Hematology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing